Capital Raising
TANFAC Industries Raises ₹173.5 Crore Through Preferential Issue to Accelerate Growth Plans
NSE
not listed
BSE
506854
TANFAC Industries Limited has approved a preferential issue of 7,41,082 equity shares at ₹2,341 per share, aggregating ₹173.5 crore, subject to shareholder approval. The capital raise follows the company’s recently completed Qualified Institutional Placement (QIP) of approximately ₹250 crore, taking the combined fundraising to ₹423.5 croreto support expansion, strengthen its fluorochemicals portfolio, and enhance long-term growth.
PRICE-SENSITIVE TRIGGER
Event: Board approves preferential issue of equity shares to promoters and institutional investors.
Type: Capital Raising
Impact: Positive
Immediate Effect: The preferential issue strengthens TANFAC’s capital base and secures additional funding for capacity expansion, value-added fluorochemical products, and strategic growth initiatives while reaffirming promoter commitment through fresh capital infusion.
Financials:
Metrics:
- Preferential Issue Size: ₹173.5 crore
- Issue Price: ₹2,341 per equity share
- Equity Shares Issued: 7,41,082 shares
- Promoter Contribution: ₹135 crore (Anupam Rasayan India Limited)
- Combined Capital Raised (QIP + Preferential Issue): ₹423.5 crore
- QIP Amount: Approximately ₹250 crore
- Paid-up Equity Shares (Post Issue):
- Before: 2,12,08,918 shares
- After: 2,19,50,000 shares
Highlight:
- The fresh capital follows a successful institutional fundraise and provides TANFAC with substantial financial resources to execute its expansion strategy while increasing promoter participation.
What Happened ?
TANFAC Industries Limited announced that its Board has approved a preferential allotment of equity shares worth ₹173.5 crore. The issue will be priced at ₹2,341 per share, subject to shareholder approval.
The preferential issue includes a ₹135 crore investment by promoter Anupam Rasayan India Limited, with the remaining allocation subscribed by institutional investors including:
- Alrox Enterprises Private Limited (Sun Pharma Group)
- Vivek Jain (Action Group)
- Tatvam Trade (Niveshaay Investments)
Following its recently completed ₹250 crore Qualified Institutional Placement (QIP), the company will have raised a combined ₹423.5 crore to fund strategic expansion initiatives.
Key Details
Capital Allocation:
The proceeds from the combined fundraising will support:
- Expansion in the R-32 refrigerant gas business.
- Growth of the company’s value-added fluorochemical product portfolio.
- Capacity expansion projects.
- Strategic investments to improve manufacturing capabilities.
- Strengthening the balance sheet to support long-term growth.
Strategic Significance:
The fundraising reflects:
- Continued promoter commitment through significant capital participation.
- Strong institutional investor confidence.
- Enhanced financial flexibility to execute expansion projects.
- Improved alignment of promoter and shareholder interests.
- Stronger capital structure for future growth opportunities.
Investors Participating:
- Promoter
- Anupam Rasayan India Limited – ₹135 crore
- Institutional Investors
- Alrox Enterprises Private Limited (Sun Pharma Group)
- Vivek Jain (Action Group)
- Tatvam Trade (Niveshaay Investments)
Investor Relevance:
The transaction is a significant capital allocation event that:
- Improves liquidity for expansion initiatives.
- Supports entry into higher-value fluorochemical segments.
- Reinforces promoter confidence through additional investment.
- Reduces funding constraints for future capacity growth.
- Positions the company for sustained long-term expansion in specialty chemicals.
Risk Analysis
Summary:
- The preferential issue remains subject to shareholder approval. The success of the capital deployment will depend on timely execution of expansion projects, demand growth in fluorochemicals, and efficient utilization of the newly raised funds.
Key Risks:
- Shareholder approval is pending.
- Project execution and commissioning risks.
- Demand fluctuations in fluorochemical markets.
- Return on invested capital depends on successful expansion.
- Commodity price and industry cycle risks may affect profitability.
Worst Case:
- Delays in project execution or weaker-than-expected demand could postpone returns from the capital raise and reduce the expected benefits of the expansion plans.
Risk Level: Medium
Company Commentary
- Managing Director Afzal Malkani stated that the successful completion of the QIP followed by the proposed preferential issue represents an important milestone in TANFAC’s growth journey. He highlighted that the capital raises strengthen the company’s financial position, enhance execution capability for planned investments, maintain a prudent capital structure, and support the creation of long-term shareholder value.
Official Exchange Filing: TANFAC Industries Limited
